Safety, Clinical Outcome, and XXXX Rate of Femoropopliteal Stenting Using a 4F Compatible Delivery System.

@entity1 @entity64 @entity174 @entity63 @entity5 @entity613 @entity583
OBJECTIVE: To determine the safety, clinical outcome, and @entity174 rate of femoropopliteal interventions using 4F stents. METHODS: Between January 2010 and December 2011, 112 symptomatic @entity1 were treated by stent implantation. Ten @entity1 were lost to follow up; therefore, 102 @entity1 (62 @entity1 ; mean age 66.4      10.1  years) were retrospectively analyzed. The indication for femoropopliteal revascularization was severe @entity613 (Rutherford-Becker score  =  3) in 63 (62%) @entity1 and chronic @entity63 (Rutherford-Becker score  =  4-6) in 39 (38%). Follow up included palpation of peripheral pulses and measurement of ankle brachial index. In @entity1 with suspected in-stent restenosis duplex ultrasonography was performed. In 2013, @entity1 were asked to return for a fluoroscopic examination of the stents. RESULTS: 114 lesions (Trans-Atlantic InterSociety Consensus-C and D, n  =  45) were treated with 119 stents (Astron Pulsar, n  =  42; Pulsar-18, n  =  77). Lesions were long (>= 100  mm) in 49 cases and heavily calcified in 35. Stents were long (>= 120  mm) in 46 cases. Ten stents were partially overlapped. The technical and clinical success rates were 100%. Two puncture related complications were noted, neither of which required surgical repair. Eleven @entity1 died ( @entity583 , n  =  4; @entity64 , n  =  2; @entity5 , n  =  5) and nine @entity1 underwent major amputation (above knee, n  =  4). The primary patency rate was 83% at 6 months and 80% at 12 months. The primary assisted patency rate was 97% at 6 months and 94% at 12 months. The secondary patency rate was 86% at 6 months and 85% at 12 months. The prevalence of @entity174 was 26% (type III and IV, 10%) after an average follow up of 25 months. CONCLUSION: Femoropopliteal stenting using a 4F compatible delivery system can be accomplished with a low complication rate, acceptable @entity174 rate, and with similar 12 month patency and revascularization rates as their 6F counterparts.
